{"product_id":"noggin-antibody-nog-bha17106243","title":"Noggin Antibody \/ NOG","description":"\u003ch2\u003eOverview\u003c\/h2\u003e\u003cp\u003eNoggin Antibody \/ NOG is a research-use-only Rabbit polyclonal (rabbit origin) Rabbit IgG directed against \u003cstrong\u003eNoggin \/ NOG\u003c\/strong\u003e. It is supplied for interpretation-focused detection and comparative profiling in WB, IHC, Direct ELISA. \u003c\/p\u003e\n\u003ch2\u003eKey elements and design rationale\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eTarget context:\u003c\/strong\u003e This antibody is raised against \u003cem\u003eA recombinant human protein corresponding to amino acids L43-T153 was used as the immunogen for the Noggin antibody.\u003c\/em\u003e. Epitope context matters because isoforms, processing, and post-translational modifications can change what is accessible in a given assay.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eFormat:\u003c\/strong\u003e Antigen affinity purified. Format influences background and compatibility with different detection chemistries; conjugated formats (when present) can simplify multiplexing and reduce reliance on secondary reagents.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eSpecies reactivity:\u003c\/strong\u003e Human, Mouse, Rat. Cross-species performance can vary with sequence divergence and epitope conservation, so interpretation should be anchored with appropriate biological controls.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eApplications:\u003c\/strong\u003e WB, IHC, Direct ELISA. These indicate assay contexts where the antibody is commonly applied; actual performance depends on sample type and processing.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eLimitations:\u003c\/strong\u003e This Noggin antibody is available for research use only.. Consider these constraints when selecting controls and when comparing results across sample matrices.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003ePolyclonal reagents can differ in how they recognize epitope features. Monoclonal antibodies often provide more consistent epitope targeting across lots, while polyclonal preparations may broaden recognition across related epitope variants. \u003c\/p\u003e\n\u003ch2\u003eBiological background\u003c\/h2\u003e\u003cp\u003e\u003cstrong\u003eNoggin \/ NOG\u003c\/strong\u003e refers to the gene\/protein target stated in the product record. Protein targets can exhibit context-dependent expression, regulated turnover, isoform diversity, and post-translational modifications that affect apparent molecular weight and epitope accessibility. For curated functional annotation, sequence features, and expression context, consult \u003ca href=\"https:\/\/www.uniprot.org\/uniprotkb\/Q13253\/entry\"\u003eUniProtKB Q13253\u003c\/a\u003e, \u003ca href=\"https:\/\/www.ensembl.org\/\"\u003eEnsembl\u003c\/a\u003e, and \u003ca href=\"https:\/\/www.proteinatlas.org\/\"\u003eHuman Protein Atlas\u003c\/a\u003e.\u003c\/p\u003e\n\u003ch2\u003eResearch relevance and current trends\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003eIntegrating antibody-based detection with single-cell and spatial atlasing efforts to connect RNA programs with protein-level abundance and localization in defined cell states.\u003c\/li\u003e\n\u003cli\u003eExpanding multiplexed imaging and high-content screening, where reagent specificity, cross-reactivity risk, and channel design (including direct conjugates) become central to interpretation.\u003c\/li\u003e\n\u003cli\u003eGrowing emphasis on reproducibility and application-specific validation frameworks (e.g., genetic perturbation controls, orthogonal measurements, and independent antibody strategies) when drawing mechanistic conclusions.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003ch2\u003eCommon research applications\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eWestern blot (WB):\u003c\/strong\u003e commonly used to compare relative abundance\/size (e.g., band intensity or mobility shifts) between conditions.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eImmunohistochemistry (IHC):\u003c\/strong\u003e commonly used to compare tissue- and cell-type–specific expression patterns in situ.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eDirect ELISA:\u003c\/strong\u003e commonly used for qualitative\/quantitative detection where compatible with the assay context.\u003c\/li\u003e\n\u003c\/ul\u003e\u003cp\u003eInterpretation typically focuses on relative differences (presence\/absence, fold-changes, compartment shifts, or population-level shifts) rather than absolute quantitation. When signal changes are observed, they may reflect altered expression, altered localization\/trafficking, changes in modification state, or differences in sample composition; orthogonal readouts and appropriate controls help distinguish these possibilities.\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication details (record-specific):\u003c\/strong\u003e Western Blot: 0.5-1ug\/ml,Immunohistochemistry (FFPE): 2-5ug\/ml,Direct ELISA (recombinant human protein): 0.1-0.5ug\/ml (BSA-free format available)\u003c\/p\u003e\u003cp\u003e\u003cstrong\u003eApplication notes (record-specific):\u003c\/strong\u003e Optimal dilution of the Noggin antibody should be determined by the researcher.\u003c\/p\u003e\n\u003ch2\u003eNotes for experimental interpretation\u003c\/h2\u003e\u003cul\u003e\n\u003cli\u003e\n\u003cstrong\u003eProduct description (record-specific):\u003c\/strong\u003e The secreted polypeptide, encoded by NOG gene, binds and inactivates members of the transforming growth factor-beta (TGF-beta) superfamily signaling proteins, such as bone morphogenetic protein-4 (BMP4). By diffusing through extracellular matrices more efficiently than members of the TGF-beta superfamily, this protein may have a principal role in creating morphogenic gradients. The protein appears to have pleiotropic effect, both early in development as well as in later stages. It was originally isolated from Xenopus based on its ability to restore normal dorsal-ventral body axis in embryos that had been artificially ventralized by UV treatment. The results of the mouse knockout of the ortholog suggest that it is involved in numerous developmental processes, such as neural tube fusion and joint formation. Recently, several dominant human NOG mutations in unrelated families with proximal symphalangism (SYM1) and multiple synostoses syndrome (SYNS1) were identified; both SYM1 and SYNS1 have multiple joint fusion as their principal feature, and map to the same region (17q22) as this gene. All of these mutations altered evolutionarily conserved amino acid residues. The amino acid sequence of this human gene is highly homologous to that of Xenopus, rat and mouse.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003ePotential confounders:\u003c\/strong\u003e isoforms, proteolytic processing, and PTMs can change epitope presentation and apparent size; fixation\/denaturation state can also expose or mask epitopes. Species differences near the epitope may affect cross-reactivity.\u003c\/li\u003e\n\u003cli\u003e\n\u003cstrong\u003eControl concepts:\u003c\/strong\u003e include genetic perturbation (KO\/KD) or overexpression comparisons, orthogonal measurement (e.g., transcript or proteomics), and independent antibody\/epitope strategies. For conjugated reagents, include staining-only\/background controls appropriate to the detection chemistry.\u003c\/li\u003e\n\u003c\/ul\u003e\n\u003cp\u003eImmunogen\/epitope context is described as: \u003cem\u003eA recombinant human protein corresponding to amino acids L43-T153 was used as the immunogen for the Noggin antibody.\u003c\/em\u003e. Monoclonal and polyclonal formats differ in epitope breadth; this can influence sensitivity to sequence variants, isoforms, or PTM-dependent recognition.\u003c\/p\u003e\n\u003c!-- Sources (internal):\n- UniProtKB entry Q13253 (UniProt Consortium): https:\/\/www.uniprot.org\/uniprotkb\/Q13253\/entry\n- Ensembl genome browser (EMBL-EBI \/ Wellcome Sanger): https:\/\/www.ensembl.org\/\n- The Human Protein Atlas (KTH \/ SciLifeLab): https:\/\/www.proteinatlas.org\/\n- A proposal for validation of antibodies (Uhlén et al., Nature Methods, 2016): https:\/\/www.nature.com\/articles\/nmeth.3995.pdf\n- Getting to reproducible antibodies: the rationale for sequenced recombinant characterized reagents (Bradbury \u0026 Plückthun, PEDS, 2015): https:\/\/academic.oup.com\/peds\/article\/28\/10\/303\/1478378\n- Standardize antibodies used in research (Bradbury, Plückthun et al., Nature, 2015): https:\/\/www.nature.com\/articles\/518027a.pdf\n--\u003e","brand":"NSJ Bioreagents","offers":[{"title":"0.5mg\/ml if reconstituted with 0.2ml sterile DI water \/ 100 ug","offer_id":53210393510253,"sku":"R32957","price":462.47,"currency_code":"USD","in_stock":true}],"thumbnail_url":"\/\/cdn.shopify.com\/s\/files\/1\/0949\/7424\/7277\/files\/get_image_2c5839fe-acd6-4037-bcc2-a2c5c727537b.jpg?v=1775785831","url":"https:\/\/www.ebiohippo.com\/products\/noggin-antibody-nog-bha17106243","provider":"BioHippo","version":"1.0","type":"link"}